Finance News – Glp
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
The weight loss drug boom has barely begun. How big can it get?
The rising popularity of GLP-1 medications, including Ozempic, positions them to generate substantial revenue, potentially surpassing established blockbuster drugs like statins in...
Read Full Article →Slim pickings: grocery sales down as Brits turn to weight-loss jabs
The increasing adoption of prescription medications for weight management is contributing to reduced grocery store revenues, as consumers adjust their purchasing habits beyond typi...
Read Full Article →How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →WeightWatchers scraps business model to team up with anti-obesity drugs provider
The collaboration with a pharmaceutical company offering GLP-1 treatments represents a strategic move for the brand to diversify revenue streams and address declining market compet...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Weight loss drugs are squeezing the food industry
The rapid success of GLP-1 medications is driving substantial revenue growth for pharmaceutical companies while simultaneously reducing consumer spending and demand within the food...
Read Full Article →Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom
WeightWatchers has filed for bankruptcy due to over $1 billion in debt, aiming to restructure its finances while shifting focus toward weight loss medications such as GLP-1 treatme...
Read Full Article →Weight loss drugs can help employers cut health care costs, study says
Employers may experience reduced healthcare expenses over time by investing in costly GLP-1 medications, as a comprehensive study of insurance claims indicates savings become appar...
Read Full Article →